Week's news analysis

Siegfried begins construction of a new global
R&D Center for Drug Substances in Evionnaz

By Editors - 26 April 2023
From left: Sophia Dini (State Council Delegate for Economy and Innovation), Beat Rieder (Council of State VS, Die Mitte), Valerie Santacrocce-Tachini (President of the municipality Evionnaz), Wolfgang Wienand (CEO Siegfried), Mar cel Signer (Site Head Siegfried Evionnaz), Irene Wosgien (COO DS Siegfried), Jürgen Roos (CSO Siegfried), Andreas Ca sutt (VRP Siegfried)

Siegfried, broke ground for its new global Research and Develop ment (R&D) Center for Drug Substances at its site in Evionnaz, Switzerland.

The new R&D Center will begin its operations in 2024 and, together with the R&D Center in Zofingen, will significantly increase Siegfried's R&D capacity to drive future growth.

At this new facility, for which Siegfried will invest up to CHF 25 million, more than 100 highly skilled specialists will work closely with Siegfried's customers to bring their precious innovations to industrial scale.

The R&D Center will host advanced chemical and analytical facilities and state-of-the-art laboratories and will offer chemical process R&D and analytical development services for the entire Drug Substances network. With this project, Siegfried is further strengthening its site in Evionnaz, which is a key pillar within its global Drug Sub stances network.

Siegfried has inaugurated, in March, its new Development Center for Drug Products at its two Spanish sites in Barberà del Vallès and El Masnou near Barcelona (Spain). The Development Center with its state-of-the art laboratories and flexible pilot capacities is set to become Siegfried's global research and development hub for its Drug Products sites, strengthening the global network.

On the move since 150 years: Siegfried demonstrated its resilience and delivered a strong performance for the full year 2022. Net sales reached 1.229 billion Swiss francs (CHF), an increase of 15.6 percent in local currencies (2021: CHF 1.102 billion), supported by both, Drug Substances and Drug Products. Core EBITDA grew from CHF 207.2 million to now CHF 272.5 million, 31.5 percent higher than 2021

TO READ Siegfried opens global Development Center for Drug Products in Barcelona

Go to Top